Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen S, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.

Radiother Oncol. 2019 Mar 15;135:74-77. doi: 10.1016/j.radonc.2019.02.010. [Epub ahead of print]

PMID:
31015173
2.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
3.

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.

Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group.

J Immunother Cancer. 2019 Apr 3;7(1):99. doi: 10.1186/s40425-019-0579-z.

4.

Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.

Radiother Oncol. 2019 Apr;133:163-166. doi: 10.1016/j.radonc.2018.12.014. Epub 2019 Jan 31.

PMID:
30935574
5.

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.

Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.

PMID:
30922878
6.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A.

Lung Cancer. 2019 Mar;129:35-40. doi: 10.1016/j.lungcan.2018.12.025. Epub 2019 Jan 15.

PMID:
30797489
7.

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.

D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaioli S, Tumedei MM, Incarbone M, Cappuzzo F.

Oncotarget. 2019 Jan 15;10(5):561-572. doi: 10.18632/oncotarget.26529. eCollection 2019 Jan 15.

8.

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations.

Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, Chiari R, Rocco D, Genova C, Sini C, Cortinovis D, Pilotto S, Landi L, Bennati C, Camerini A, Toschi L, Putzu C, Cerea G, Spitaleri G, Cappuzzo F, de Marinis F.

Clin Lung Cancer. 2019 Mar;20(2):e186-e194. doi: 10.1016/j.cllc.2018.11.005. Epub 2018 Nov 20.

PMID:
30563752
9.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.

Garassino MC, Crinò L, Catino A, Ardizzoni A, Cortesi E, Cappuzzo F, Bordi P, Calabrò L, Barbieri F, Santo A, Altavilla G, Ambrosio F, Mini E, Vasile E, Morgillo F, Scoppola A, Bengala C, Follador A, Tedde N, Giannarelli D, Lo Russo G, Vitiello F.

Tumour Biol. 2018 Nov;40(11):1010428318815047. doi: 10.1177/1010428318815047.

PMID:
30486741
10.

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.

Passiglia F, Cappuzzo F, Alabiso O, Bettini AC, Bidoli P, Chiari R, Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D, Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca E, Turci D, Galetta D.

Br J Cancer. 2019 Jan;120(1):57-62. doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31.

PMID:
30377342
11.

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.

Jiang T, Su C, Ren S, Cappuzzo F, Rocco G, Palmer JD, van Zandwijk N, Blackhall F, Le X, Pennell NA, Zhou C; written on behalf of the AME Lung Cancer Collaborative Group.

J Thorac Dis. 2018 Jul;10(7):3909-3921. doi: 10.21037/jtd.2018.07.61. Review.

12.

How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

Zhang Y, Shen J, Simone CB 2nd, Cappuzzo F, Fong KM, Rosell R, Chang JY, Ampollini L, Choi JI, He J, Jiang T; Written on behalf of AME Lung Cancer Cooperative Group.

J Thorac Dis. 2018 Jun;10(6):3883-3890. doi: 10.21037/jtd.2018.06.101. No abstract available.

13.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID:
30014881
14.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

15.

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS.

J Clin Oncol. 2018 Aug 1;36(22):2251-2258. doi: 10.1200/JCO.2017.77.4794. Epub 2018 May 16.

PMID:
29768118
16.

Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.

Smit EF, Garon EB, Reck M, Cappuzzo F, Bidoli P, Cohen RB, Gao L, O'Brien LM, Lee P, Zimmermann A, Ferry DR, Melemed AS, Pérol M.

Cancer Chemother Pharmacol. 2018 Jul;82(1):77-86. doi: 10.1007/s00280-018-3560-5. Epub 2018 May 2.

PMID:
29721850
17.

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).

Vecchiarelli S, Passiglia F, D'Incecco A, Gallo M, De Luca A, Rossi E, D'Incà F, Minuti G, Landi L, Bennati C, Spreafico M, D'Arcangelo M, Mazza V, Normanno N, Cappuzzo F.

Oncotarget. 2018 Apr 3;9(25):17554-17563. doi: 10.18632/oncotarget.24785. eCollection 2018 Apr 3.

18.

Lung Cancer Update 2017: from the test tube to the bed.

Bertolaccini L, Cappuzzo F, Solli P.

Ann Transl Med. 2018 Mar;6(5):86. doi: 10.21037/atm.2018.02.25. No abstract available.

19.

HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

Cappuzzo F, Landi L.

Clin Cancer Res. 2018 Jun 1;24(11):2470-2472. doi: 10.1158/1078-0432.CCR-18-0198. Epub 2018 Mar 1.

PMID:
29496760
20.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

21.

Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.

Cappuzzo F, Soo R, Hochmair M, Schuler M, Lam KC, Stehle G, Cseh A, Lorence RM, Linden S, Forman ND, Hilbe W, Jazieh AR, Tsai CM.

Future Oncol. 2018 Jun;14(15):1477-1486. doi: 10.2217/fon-2017-0666. Epub 2018 Jan 29.

22.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M.

Lung Cancer. 2017 Oct;112:181-187. doi: 10.1016/j.lungcan.2017.07.038. Epub 2017 Aug 5.

23.

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.

Landi L, Cappuzzo F.

J Thorac Dis. 2017 Aug;9(8):2311-2314. doi: 10.21037/jtd.2017.07.76. No abstract available.

24.

Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.

Mazza V, Cappuzzo F.

Appl Clin Genet. 2017 Jul 26;10:49-56. doi: 10.2147/TACG.S103471. eCollection 2017. Review.

25.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

26.

Crizotinib: from discovery to accelerated development to front-line treatment.

Blackhall F, Cappuzzo F.

Ann Oncol. 2018 Apr 1;29(4):1073. doi: 10.1093/annonc/mdx121. No abstract available.

PMID:
28398575
27.

Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC.

Landi L, Cappuzzo F.

Transl Lung Cancer Res. 2016 Dec;5(6):579-587. doi: 10.21037/tlcr.2016.12.05. Review.

28.

The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer.

Gemmill RM, Nasarre P, Nair-Menon J, Cappuzzo F, Landi L, D'Incecco A, Uramoto H, Yoshida T, Haura EB, Armeson K, Drabkin HA.

Sci Signal. 2017 Jan 17;10(462). pii: eaag0528. doi: 10.1126/scisignal.aag0528.

29.

Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches.

Mazza V, Cappuzzo F.

J Thorac Dis. 2016 Oct;8(10):E1348-E1350. No abstract available.

30.

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Drilon A, Cappuzzo F, Ou SI, Camidge DR.

J Thorac Oncol. 2017 Jan;12(1):15-26. doi: 10.1016/j.jtho.2016.10.014. Epub 2016 Oct 26. Review.

31.

Crizotinib: from discovery to accelerated development to front-line treatment.

Blackhall F, Cappuzzo F.

Ann Oncol. 2016 Sep;27 Suppl 3:iii35-iii41. doi: 10.1093/annonc/mdw304. Review.

PMID:
27573754
32.

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F.

Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14.

PMID:
27565910
33.

EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.

Giannini R, Lupi C, Sensi E, Alì G, Proietti A, Boldrini L, Servadio A, Giordano M, Macerola E, Bruno R, Borrelli N, Chella A, Melfi F, Lucchi M, Ribechini A, Vasile E, Cappuzzo F, Mussi A, Fontanini G.

Oncol Rep. 2016 Aug;36(2):1166-72. doi: 10.3892/or.2016.4874. Epub 2016 Jun 14.

PMID:
27373829
34.

Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer.

Romanidou O, Landi L, Cappuzzo F, Califano R.

Ther Adv Med Oncol. 2016 May;8(3):176-87. doi: 10.1177/1758834016631531. Epub 2016 Feb 16. Review.

35.

cMET Exon 14 Skipping: From the Structure to the Clinic.

Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C.

J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005. Epub 2016 May 17. Review.

36.

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Califano R, Romanidou O, Mountzios G, Landi L, Cappuzzo F, Blackhall F.

Drugs. 2016 May;76(8):831-40. doi: 10.1007/s40265-016-0578-z. Review.

PMID:
27129321
37.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø.

Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26.

38.

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS.

J Clin Oncol. 2016 Aug 20;34(24):2858-65. doi: 10.1200/JCO.2015.63.5888. Epub 2016 Mar 28.

PMID:
27022118
39.

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.

Pérol M, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Kowalyszyn RD, Pikiel J, Lewanski CR, Thomas M, Dakhil S, Kim JH, Karaseva N, Yurasov S, Zimmermann A, Lee P, Carter GC, Reck M, Cappuzzo F, Garon EB.

Lung Cancer. 2016 Mar;93:95-103. doi: 10.1016/j.lungcan.2016.01.007. Epub 2016 Jan 19.

PMID:
26898621
40.

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Del Re M, Tiseo M, Bordi P, D'Incecco A, Camerini A, Petrini I, Lucchesi M, Inno A, Spada D, Vasile E, Citi V, Malpeli G, Testa E, Gori S, Falcone A, Amoroso D, Chella A, Cappuzzo F, Ardizzoni A, Scarpa A, Danesi R.

Oncotarget. 2017 Feb 21;8(8):13611-13619. doi: 10.18632/oncotarget.6957.

41.

Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.

Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M, Tan EH, Delmar P, Klingelschmitt G, Yin AY, Spleiss O, Wu L, Shames DS.

J Thorac Oncol. 2016 Apr;11(4):545-55. doi: 10.1016/j.jtho.2015.12.107. Epub 2016 Jan 8.

42.

microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.

Gasparini P, Cascione L, Landi L, Carasi S, Lovat F, Tibaldi C, Alì G, D'Incecco A, Minuti G, Chella A, Fontanini G, Fassan M, Cappuzzo F, Croce CM.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.

43.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.

Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.

PMID:
26598547
44.

Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Landi L, Cappuzzo F.

Expert Rev Clin Pharmacol. 2016;9(2):203-14. doi: 10.1586/17512433.2016.1122518. Epub 2015 Dec 16. Review.

PMID:
26582431
45.

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.

Minuti G, D'Incecco A, Cappuzzo F.

Drugs Aging. 2015 Nov;32(11):907-16. doi: 10.1007/s40266-015-0305-6. Review.

PMID:
26446154
46.

Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials.

Osarogiagbon RU, Cappuzzo F, Ciuleanu T, Leon L, Klughammer B.

Transl Lung Cancer Res. 2015 Aug;4(4):465-74. doi: 10.3978/j.issn.2218-6751.2015.07.17.

47.

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.

Barni S, Maiello E, Di Maio M, Ardizzoni A, Cappuzzo F, Maranzano E, Novello S, Bennati C, Ori A, Rizzoli S, Crinò L; RIGHT-3 study group.

Lung Cancer. 2015 Nov;90(2):234-42. doi: 10.1016/j.lungcan.2015.08.005. Epub 2015 Aug 19.

48.

Experience with erlotinib in the treatment of non-small cell lung cancer.

Landi L, Cappuzzo F.

Ther Adv Respir Dis. 2015 Aug;9(4):146-63. doi: 10.1177/1753465815588053. Epub 2015 Jun 10. Review.

PMID:
26063687
49.

Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study.

D'Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D'Incecco A, Landi L, Apuzzo T, Rossi E, Sani S, Stassi G, Cappuzzo F.

PLoS One. 2015 May 8;10(5):e0125037. doi: 10.1371/journal.pone.0125037. eCollection 2015.

50.

Onartuzumab in lung cancer: the fall of Icarus?

Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F.

Expert Rev Anticancer Ther. 2015 May;15(5):487-9. doi: 10.1586/14737140.2015.1031219. Epub 2015 Mar 30.

PMID:
25818471

Supplemental Content

Loading ...
Support Center